web analytics
25 C
Munich
Thursday, August 11, 2022

Bulls Take Charge of SPO Global Inc. (OTCMKTS: SPOM)

SPO Global Inc. (OTCMKTS: SPOM) has seen a surge in price and volume after the Company announced its CEO Lu Fengyu attended the Signing ceremony of strategic framework cooperation to build “Qilu SPM International Stroke (Jinan) Hospital”. This Hospital will be jointly established by Canada SOTA Biomed Investments Inc., SD Superior Medical Group & Jinan Zhongke Xilai Equipment Co., Ltd. Jinan High-tech Park Bonded Area CEO Liu Yechao, and directors from related governments departments, Mr. Lu Fengyou, Chairman of Canada SOTA Biomed Investments Inc., Chairman of SD Superior Medical Group under Gerpang Healthcare Group. The hospital project will be renovated from the existing building in bonded area with a construction area of 20,000 square meters and nearly 300 in-patient beds. It is expected to pilot run operation in June 2021.

SPOM is the reverse merger runner that exploded from pennies to $0.68 highs back in February as well as another huge run in May. The stock has been among the most volatile in small caps and has attracted legions of shareholders along the way.

SPO Global Inc. (OTC Markets: SPOM) recently completed its merger with Gerpang Healthcare Group. Its subsidiary, Shandong Gerpang Biotechnology Co., Ltd. is an innovative and technological private enterprise located in the pharmaceutical Valley Industrial Park of Jinan high tech Zone. Its main business scope includes biomedical R&D, medical information software development and sales, medical high-tech introduction, medical high-quality consumables production and sales, health care products, drugs, medical equipment consumables agency and sales. According to its website:  GP Healthcare Group is located in Jinan Pharma Valley Industrial Park, High-tech District. It is an innovative technology-based private and high-tech enterprise. The group was founded by School of Pharmaceutical Science of Shandong University Prof. Fengyou Lu. Mr. Lu possesses 24 years of market operating experience in pharmaceutical market in the Greater China region, and has successfully run four foreign-funded enterprises and large private enterprises. The main business scope of the Group includes bio-pharmaceutical R&D, development and sales of medical informatization software, medical high-tech introduction, production and sales of medical quality supplies, dietary supplement, medicine, as well as agents and sales of medical equipment supplies. There are 220 staff. Besides the Group had more than 10 international and national patents, and its annual turnover nearly reaches RMB 1 billion.

To Find out the inside Scoop on SPOM  Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

SPOM

Microcapdaily has been reporting on SPOM along the way stating on February 13 when the stock started running stating at the time: SPOM was up over 600% in afternoon trading after the Company announced it has signed a definitive agreement to acquire Gerpang Healthcare Group of Shandong in a reverse merger agreement. Gerpang has a staff of over 220 people, more than 10 international and national patents, and an annual turnover of approximately RMB 1 billion.

According to today’s press release the hospital project will be renovated from the existing building in bonded area with a construction area of 20,000 square meters and nearly 300 in-patient beds. It is expected to pilot run operation in June 2021. This hospital will be the first international specialist hospital in Shandong Province that integrates treatment and rehabilitation by the world’s top stroke experts. The hospital introduces the most advanced interventional therapy technology in North America, in accordance with international rehabilitation nursing standards and operation management system, to create the world’s top stroke specialist hospital. After the hospital is completed, it will receive 5,000 patients and rehabilitation treatment every year.

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $25 million market valuation SPOM is virtually debt free with a fairly tight stock structure already doing significant sales reporting $3.6 million in revenues for the Quarter ended March 31, 2020. Investors believe these numbers do not include Gerpang. SPOM has been among the most volatile and explosive RM plays in small caps. The new Company Gerpang Healthcare Group of Shandong, China says they have a staff of 220 people, more than 10 international and national patents, and an annual turnover of approximately RMB 1 billion. The recent run in price comes after the Company announced its CEO Lu Fengyu attended the Signing ceremony of strategic framework cooperation to build “Qilu SPM International Stroke (Jinan) Hospital” The hospital project will be renovated from the existing building in bonded area with a construction area of 20,000 square meters and nearly 300 in-patient beds. It is expected to pilot run operation in June 2021.  We will be updating on SPOM on a daily basis so make sure you are subscribed to microcapdaily.com so you know what is going on with SPOM.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in SPOM either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.